| Literature DB >> 33414253 |
Mitchell N Luu1, Paul Y Wada2, Tory Levine-Hall3, Leo Hurley3, Nirmala Ramalingam2, H Nicole Tran2, Sally B Slome4.
Abstract
BACKGROUND: Despite increased efforts to promote HIV screening, a large proportion of the US population have never been tested for HIV.Entities:
Keywords: audit and feedback; clinical practice guidelines; general practice; healthcare quality improvement
Year: 2021 PMID: 33414253 PMCID: PMC7797258 DOI: 10.1136/bmjoq-2020-000988
Source DB: PubMed Journal: BMJ Open Qual ISSN: 2399-6641
Provider demographics and knowledge of HIV screening guidelines and perceived barriers
| Provider demographics | No. |
| Male | 7 |
| Female | 13 |
| Internal medicine | 7 |
| Family medicine | 13 |
| Average age (years) | 40.4 |
| Average years of practice | 9 |
| I am familiar with the CDC and USPSTF guidelines for HIV screening | |
| Strongly agree and agree | 16 (84%) |
| Neither agree nor disagree, disagree, and strongly disagree | 3 (16%) |
| I feel comfortable screening my patients for HIV | |
| Strongly agree and agree | 19 (100%) |
| Neither agree nor disagree, disagree, and strongly disagree | 0 (0%) |
| Which best describes your HIV screening practice? | |
| I screen all patients, with more frequent screening based on risk factors | 11 (58%) |
| I screen my patients only if there are risk factors | 5 (26%) |
| I screen my patients once, regardless of risk factors | 2 (11%) |
| I do none of the above statements | 1 (5%) |
| On average, I screen __ patients for HIV in a given month | |
| Fewer than 5 | 3 (16%) |
| 5–10 | 7 (37%) |
| 11–20 | 5 (26%) |
| More than 20 | 4 (21%) |
| What are the barriers for you in screening patients for HIV? (select all that apply) | |
| Competing priorities | 11 (58%) |
| Insufficient time | 8 (42%) |
| Lack of perceived risk for patient | 7 (37%) |
| Cultural barriers | 4 (21%) |
| Fear/concern of offending patient | 4 (21%) |
| Burdensome consent process | 4 (21%) |
| Lack of provider knowledge/training | 1 (5%) |
| Discomfort discussing sexual history and identifying high-risk individuals | 0 (0%) |
| Uncertain follow-up and disclosures of test results (specifically if positive) | 0 (0%) |
CDC, Centers for Disease Control and Prevention; USPSTF, United States Preventive Services Task Force.
Counts and percentages of eligible members ever screened for HIV over 12-month intervention
| Baseline data (1 January2018 to 31 March 2018) | Interval 1 (1 April 2018 to 30 June 2018) | Interval 2 (1 July 2018 to 30 September 2018) | Interval 3 (1 October 2018 to 31 December 2018) | Interval 4 (1 January 2019 to 31 March 2019) | |
| Cohort PCP | 9606/19 008 | 9415/18 092 | 9112/17 104 | 8434/15 346 | 7845/14 029 |
| KPOAK | 62 471/163 968 | 62 274/159 730 | 61 463/154 829 | 61 475/151 947 | 60 572/147 565 |
| KPNC | 851 061/2 912 259 | 845 346/2 838 611 | 838 159/2 765 229 | 832 751/2 703 076 | 818 622/2 612 695 |
| Cohort PCP | 1.5% | 1.2% | 1.1% | 1.6% | |
| KPOAK | 0.9% | 0.7% | 0.8% | 0.6% | |
| KPNC | 0.6% | 0.5% | 0.5% | 0.5% |
KPNC, Kaiser Permanente Northern California; KPOAK, Kaiser Permanente Oakland Medical Center; PCP, primary care physician.
Figure 1HIV screening report card for cohort primary care physicians.
Estimated increases in HIV screening over 12-month intervention
| % screened at baseline | Change in % screened over 12 months | Comparison of trend in % screened over time by reference group | |||
| 95% confidence limit | P value | P value | P value | ||
| Cohort | 50.5% | 2.6% (1.9%, 3.2%) | <0.0001 | 0.022 | 0.073 |
| KPOAK | 38.1% | 1.9% (1.6%, 2.1%) | <0.0001 | ** | Ref |
| KPNC | 29.2% | 1.8% (1.7%, 1.8%) | <0.0001 | Ref | ** |
**P value: 0.328.
KPNC, Kaiser Permanente Northern California; KPOAK, Kaiser Permanente Oakland Medical Center.